{
    "nct_id": "NCT03722511",
    "official_title": "A Phase 2 Study Evaluating a Proprietary Amino Acid Based Medical Food (Enterade®) in Patients With Quality of Life Limiting Diarrhea Due to Carcinoid Syndrome and Other Neuroendocrine Tumors (NET).",
    "inclusion_criteria": "* Cohort 1: Participants must have histopathologically confirmed neuroendocrine tumor with 4 or more bowel movements per day on standard anti-diarrheal regimen (which may or may not include somatostatin analogs and telotristat), AND an elevated serum serotonin or plasma serotonin above the upper limit of normal per reference lab.\n* Cohort 2: Participants who have histopathologically confirmed neuroendocrine tumor and have 4 or more bowel movements per day on standard anti-diarrheal regimen (which may or may not include somatostatin analogs and telotristat), but are below the cut-point for serotonin elevation.\n* Age equal to or greater than 18 years old.\n* ECOG performance status ≤2 (Karnofsky ≥60%)\n* Ability to tolerate thin liquids by mouth at the time of enrollment.\n* Ability to understand and the willingness to sign a written informed consent document.\n* Subject who are willing to take enterade® as instructed will be eligible.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known allergy to Stevia.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active Clostridium difficile infection or history of Clostridium difficile infection.\n* Participants with active clostridium difficile infection will be ineligible for this study.\n* Participants with a history of inflammatory bowel disease, irritable bowel syndrome, bariatric surgery and/or Celiac disease.\n* Participants with psychiatric illness/social situations that would limit compliance with study requirements.\n* Patients who have had enterade® within the past 12 months.",
    "miscellaneous_criteria": ""
}